PT Industri Jamu dan Farmasi Sido Muncul Tbk Logo

PT Industri Jamu dan Farmasi Sido Muncul Tbk

SIDO.JK

(2.2)
Stock Price

670 IDR

26.79% ROA

28.86% ROE

16.07x PER

Market Cap.

15.600.000.000.000 IDR

0.28% DER

6.85% Yield

26.66% NPM

PT Industri Jamu dan Farmasi Sido Muncul Tbk Stock Analysis

PT Industri Jamu dan Farmasi Sido Muncul Tbk Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Fundamental Stock Analysis
# Analysis Rating
1 Dividend

Investors can take comfort in the company's unwavering commitment to dividends, as it has consistently distributed payouts over the past five years, ensuring a reliable income stream.

2 ROE

ROE surpassing expectations (29.21%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

3 ROA

This stock has a great ability to make a lot of money from the things it owns, which makes it a really good investment for smart investors.

4 DER

The stock has a minimal amount of debt (0%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

5 Buffet Intrinsic Value

The company's stock seems undervalued (1.800) by Warren Buffett's formula, indicating a promising investment opportunity as its intrinsic value exceeds the market price.

6 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

8 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

9 PBV

The stock's high Price-to-Book Value (P/BV) ratio (4.39x) suggests it's overvalued, potentially making it an expensive investment.

10 Revenue Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

11 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

PT Industri Jamu dan Farmasi Sido Muncul Tbk Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Revenue
Year Revenue Growth
2010 1.866.538.000.000
2011 2.198.273.000.000 15.09%
2012 2.391.667.000.000 8.09%
2013 2.372.364.000.000 -0.81%
2014 2.197.907.000.000 -7.94%
2015 2.218.536.000.000 0.93%
2016 2.561.806.000.000 13.4%
2017 2.573.840.000.000 0.47%
2018 2.763.292.000.000 6.86%
2019 3.067.434.000.000 9.92%
2020 3.335.411.000.000 8.03%
2021 4.020.980.000.000 17.05%
2022 3.865.523.000.000 -4.02%
2023 2.830.020.000.000 -36.59%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Research and Development Expenses
Year Research and Development Expenses Growth
2010 0
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

PT Industri Jamu dan Farmasi Sido Muncul Tbk General and Administrative Expenses
Year General and Administrative Expenses Growth
2010 13.780.000.000
2011 36.644.000.000 62.39%
2012 13.433.000.000 -172.79%
2013 25.694.000.000 47.72%
2014 22.706.000.000 -13.16%
2015 23.840.000.000 4.76%
2016 24.672.000.000 3.37%
2017 38.845.000.000 36.49%
2018 31.467.000.000 -23.45%
2019 47.137.000.000 33.24%
2020 47.695.000.000 1.17%
2021 38.601.000.000 -23.56%
2022 38.511.000.000 -0.23%
2023 40.060.000.000 3.87%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

PT Industri Jamu dan Farmasi Sido Muncul Tbk EBITDA
Year EBITDA Growth
2010 344.469.000.000
2011 454.051.000.000 24.13%
2012 512.720.000.000 11.44%
2013 655.165.000.000 21.74%
2014 556.020.000.000 -17.83%
2015 576.277.000.000 3.52%
2016 589.745.000.000 2.28%
2017 693.984.000.000 15.02%
2018 878.057.000.000 20.96%
2019 1.088.666.000.000 19.35%
2020 1.210.112.000.000 10.04%
2021 1.620.230.000.000 25.31%
2022 1.426.341.000.000 -13.59%
2023 718.980.000.000 -98.38%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Gross Profit
Year Gross Profit Growth
2010 685.934.000.000
2011 877.689.000.000 21.85%
2012 920.647.000.000 4.67%
2013 1.010.781.000.000 8.92%
2014 839.565.000.000 -20.39%
2015 883.365.000.000 4.96%
2016 1.067.664.000.000 17.26%
2017 1.161.959.000.000 8.12%
2018 1.424.391.000.000 18.42%
2019 1.680.564.000.000 15.24%
2020 1.838.783.000.000 8.6%
2021 2.286.032.000.000 19.56%
2022 2.162.613.000.000 -5.71%
2023 1.561.444.000.000 -38.5%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Net Profit
Year Net Profit Growth
2010 237.169.000.000
2011 339.935.000.000 30.23%
2012 387.538.000.000 12.28%
2013 405.943.000.000 4.53%
2014 415.193.000.000 2.23%
2015 437.474.000.000 5.09%
2016 480.525.000.000 8.96%
2017 533.799.000.000 9.98%
2018 663.849.000.000 19.59%
2019 807.689.000.000 17.81%
2020 934.016.000.000 13.53%
2021 1.260.898.000.000 25.92%
2022 1.104.714.000.000 -14.14%
2023 553.864.000.000 -99.46%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2010 8
2011 11 36.36%
2012 13 8.33%
2013 13 7.69%
2014 14 0%
2015 15 7.14%
2016 16 12.5%
2017 18 5.88%
2018 22 22.73%
2019 27 15.38%
2020 31 16.13%
2021 42 26.19%
2022 37 -16.67%
2023 18 -100%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Free Cashflow
Year Free Cashflow Growth
2010 -94.953.000.000
2011 -109.725.000.000 13.46%
2012 -180.443.000.000 39.19%
2013 -205.682.000.000 12.27%
2014 -292.978.000.000 29.8%
2015 -180.665.000.000 -62.17%
2016 -158.163.000.000 -14.23%
2017 -334.961.000.000 52.78%
2018 -236.963.000.000 -41.36%
2019 699.564.000.000 133.87%
2020 940.615.000.000 25.63%
2021 1.076.764.000.000 12.64%
2022 932.807.000.000 -15.43%
2023 342.763.000.000 -172.14%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Operating Cashflow
Year Operating Cashflow Growth
2010 1.500.000.000
2011 1.039.000.000 -44.37%
2012 1.037.000.000 -0.19%
2013 4.876.000.000 78.73%
2014 7.250.000.000 32.74%
2015 16.036.000.000 54.79%
2016 17.552.000.000 8.64%
2017 10.197.000.000 -72.13%
2018 9.991.000.000 -2.06%
2019 836.914.000.000 98.81%
2020 1.035.754.000.000 19.2%
2021 1.199.317.000.000 13.64%
2022 1.111.210.000.000 -7.93%
2023 359.431.000.000 -209.16%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Capital Expenditure
Year Capital Expenditure Growth
2010 96.453.000.000
2011 110.764.000.000 12.92%
2012 181.480.000.000 38.97%
2013 210.558.000.000 13.81%
2014 300.228.000.000 29.87%
2015 196.701.000.000 -52.63%
2016 175.715.000.000 -11.94%
2017 345.158.000.000 49.09%
2018 246.954.000.000 -39.77%
2019 137.350.000.000 -79.8%
2020 95.139.000.000 -44.37%
2021 122.553.000.000 22.37%
2022 178.403.000.000 31.31%
2023 16.668.000.000 -970.33%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Equity
Year Equity Growth
2009 174.904.000.000
2010 346.407.000.000 49.51%
2011 535.342.000.000 35.29%
2012 1.304.649.000.000 58.97%
2013 2.625.454.000.000 50.31%
2014 2.634.654.000.000 0.35%
2015 2.598.307.000.000 -1.4%
2016 2.757.878.000.000 5.79%
2017 2.895.858.000.000 4.76%
2018 2.902.614.000.000 0.23%
2019 3.064.707.000.000 5.29%
2020 3.221.740.000.000 4.87%
2021 3.471.185.000.000 7.19%
2022 3.505.475.000.000 0.98%
2023 3.407.026.000.000 -2.89%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Assets
Year Assets Growth
2009 604.472.000.000
2010 890.202.000.000 32.1%
2011 1.168.658.000.000 23.83%
2012 2.150.999.000.000 45.67%
2013 2.951.507.000.000 27.12%
2014 2.821.399.000.000 -4.61%
2015 2.796.111.000.000 -0.9%
2016 2.987.614.000.000 6.41%
2017 3.158.198.000.000 5.4%
2018 3.337.628.000.000 5.38%
2019 3.536.898.000.000 5.63%
2020 3.849.516.000.000 8.12%
2021 4.068.970.000.000 5.39%
2022 4.081.442.000.000 0.31%
2023 3.752.487.000.000 -8.77%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Liabilities
Year Liabilities Growth
2009 429.566.000.000
2010 543.793.000.000 21.01%
2011 633.314.000.000 14.14%
2012 846.348.000.000 25.17%
2013 326.051.000.000 -159.58%
2014 186.740.000.000 -74.6%
2015 197.797.000.000 5.59%
2016 229.729.000.000 13.9%
2017 262.333.000.000 12.43%
2018 435.014.000.000 39.7%
2019 472.191.000.000 7.87%
2020 627.776.000.000 24.78%
2021 597.785.000.000 -5.02%
2022 575.967.000.000 -3.79%
2023 345.461.000.000 -66.72%

PT Industri Jamu dan Farmasi Sido Muncul Tbk Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
120.43
Net Income per Share
32.36
Price to Earning Ratio
16.07x
Price To Sales Ratio
4.32x
POCF Ratio
14.2
PFCF Ratio
16
Price to Book Ratio
4.58
EV to Sales
4.1
EV Over EBITDA
11.79
EV to Operating CashFlow
13.5
EV to FreeCashFlow
15.21
Earnings Yield
0.06
FreeCashFlow Yield
0.06
Market Cap
15.600 Bil.
Enterprise Value
14.826 Bil.
Graham Number
287.56
Graham NetNet
22.03

Income Statement Metrics

Net Income per Share
32.36
Income Quality
1.6
ROE
0.29
Return On Assets
0.24
Return On Capital Employed
0.35
Net Income per EBT
0.78
EBT Per Ebit
1.02
Ebit per Revenue
0.33
Effective Tax Rate
0.22

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.57
Operating Profit Margin
0.33
Pretax Profit Margin
0.34
Net Profit Margin
0.27

Dividends

Dividend Yield
0.07
Dividend Yield %
6.85
Payout Ratio
0.42
Dividend Per Share
35.6

Operating Metrics

Operating Cashflow per Share
36.62
Free CashFlow per Share
32.5
Capex to Operating CashFlow
-0.11
Capex to Revenue
-0.03
Capex to Depreciation
-76.54
Return on Invested Capital
0.28
Return on Tangible Assets
0.27
Days Sales Outstanding
0
Days Payables Outstanding
34.22
Days of Inventory on Hand
103.44
Receivables Turnover
0
Payables Turnover
10.67
Inventory Turnover
3.53
Capex per Share
-4.12

Balance Sheet

Cash per Share
26,11
Book Value per Share
113,57
Tangible Book Value per Share
109.29
Shareholders Equity per Share
113.57
Interest Debt per Share
0.32
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
-0.62
Current Ratio
6.25
Tangible Asset Value
3.279 Bil.
Net Current Asset Value
1.552 Bil.
Invested Capital
0
Working Capital
1.594 Bil.
Intangibles to Total Assets
0.03
Average Receivables
0 Bil.
Average Payables
127 Bil.
Average Inventory
461753000000
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

PT Industri Jamu dan Farmasi Sido Muncul Tbk Dividends
Year Dividends Growth
2014 27
2015 24 -12.5%
2016 25 4%
2017 26 3.85%
2018 44 40.91%
2019 64 31.25%
2020 39 -64.1%
2021 34 -18.18%
2022 36 8.33%
2023 36 -2.86%

PT Industri Jamu dan Farmasi Sido Muncul Tbk Profile

About PT Industri Jamu dan Farmasi Sido Muncul Tbk

PT Industri Jamu dan Farmasi Sido Muncul Tbk provides herbal medicines, cosmetics, and foods and beverages related to health in Indonesia. It operates through Herbal Medicine and Supplements, Food and Beverage, and Pharmacy segments. The company offers ethical and OTC products for various health interests, including ache and pain relief, antibiotics, anemia, anti-allergy, antioxidants, blood pressure, brain function, bone health, children's health, cold, flu, and cough, as well as diabetes, digestion, energy and vitality, heart and cholesterol, immune system, joints and mobility, liver and detox, men's health, skin health, sleep aids, tumor and cancer, weight management, women's health, and others. In addition, it is also involved in commerce, land transportation, wastewater treatment, and plantation and printing activities. The company was founded in 1940 and is headquartered in Semarang, Indonesia. PT Industri Jamu dan Farmasi Sido Muncul Tbk is a subsidiary of PT Hotel Candi Baru.

CEO
Mr. David Hidayat
Employee
3.448
Address
Office Sido Muncul
Semarang, 50134

PT Industri Jamu dan Farmasi Sido Muncul Tbk Executives & BODs

PT Industri Jamu dan Farmasi Sido Muncul Tbk Executives & BODs
# Name Age
1 Mr. David Hidayat
President Director
70
2 Ms. Tiur Simamora
Corporate Secretary
70
3 Mr. Yulius Ajie
Head of Internal Audit Unit
70

PT Industri Jamu dan Farmasi Sido Muncul Tbk Competitors